The PREVAIL Study (PREVAIL)
A Clinical PeRformance EVAluatIon of a New Medtronic Coronary Drug-Coated BaLloon Catheter for the Treatment of De Novo Lesions, In-Stent Restenosis and Small Vessel Disease in Coronary Arteries: The PREVAIL Study
Sponsor: Medtronic Vascular
This NA trial investigates Coronary Artery Disease and In-stent Restenosis and is currently completed. Medtronic Vascular leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Oct 2019 — Jan 2021 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
May 2019 — Oct 2019 [monthly]
Active Not Recruiting NA
-
Nov 2018 — May 2019 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jul 2018 — Nov 2018 [monthly]
Recruiting NA
-
Jun 2018 — Jul 2018 [monthly]
Recruiting NA
-
May 2018 — Jun 2018 [monthly]
Recruiting NA
-
Oct 2017 — May 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — Oct 2017 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Medtronic Vascular
For direct contact, visit the study record on ClinicalTrials.gov .